The Next Step in the FLAURA Trial

The Next Step in the FLAURA Trial

Cancer-News

1 month
6 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC.

________

28% of patients in the global FLAURA trial were still receiving TAGRISSO at three years vs. 9% on either gefitinib or erlotinib

TAGRISSO showed a 52% reduction in risk of central nervous system disease progression or death

AstraZeneca today presented detailed overall survival (OS) results from the Phase III FLAURA trial of TAGRISSO® (osimertinib) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Results showed a statistically significant and clinically meaningful improvement in OS, a key secondary endpoint for TAGRISSO versus gefitinib or erlotinib, both of which were previous standard-of-care (SoC) treatments in this setting (HR 0.799 [95% CI, 0.641-0.997], p=0.0462).

TAGRISSO delivered a median OS of 38.6 months versus 31.8 months for the comparator arm. At three years, 28% of patients in the TAGRISSO arm and 9% of patients in the comparator arm remained on 1st-line study treatment. TAGRISSO also showed a statistically significant and clinically meaningful 52% reduction in the risk of central nervous system (CNS) disease progression, increasing the time patients with CNS metastases lived without CNS disease progression or death (HR 0.48 [95% CI, 0.26-0.86], p=0.014).1

The results were presented at the Presidential Symposium of the ESMO (European Society for Medical Oncology) 2019 Congress in Barcelona, Spain (Abstract #LBA5_PR).

José Baselga, Executive Vice President, Oncology R&D said: “TAGRISSO has set a new benchmark in EGFR-mutated non-small cell lung cancer by demonstrating a median overall survival of more than three years. We have not before seen survival benefits of this magnitude in any global Phase III trial with any such therapy. The ground-breaking data reaffirm the benefit of using TAGRISSO first and further support its use as the 1st-line standard of care in this setting.”

Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial from Winship Cancer Institute of Emory University, Atlanta, US, said: “The results of the FLAURA trial provide further evidence to support the role of osimertinib as the preferred 1st-line therapy option for patients with EGFR-mutated non-small cell lung cancer. It is highly noteworthy that 28% of patients are still being treated with 1st-line osimertinib at three years versus 9% on either gefitinib or erlotinib.”

Read here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2019/tagrisso-is-the-only-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer-to-deliver-a-median-overall-survival-of-more-than-three-years-09282019.html

Up Next Autoplay
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
18 Views
SeattleCCA 3 days
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
Category: Immunotherapy
11 Views
Cancer-News 3 days
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
7 Views
MD Anderson 4 days
KY1044 Targets ICOS @kymabltd @rcasainson
KY1044 Targets ICOS @kymabltd @rcasainson
Category: Other
3 Views
Cancer-News 4 days
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
Category: Other
6 Views
Cancer-News 4 days
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
24 Views
MD Anderson 4 days
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
Category: Other
12 Views
Cancer-News 4 days
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Category: News
8 Views
OSUCCC 4 days
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Phase 3 NINLAROTM (ixazomib) Trial as the Primary Endpoint of First-Line Maintenance Therapy in Multiple Myeloma Patients not Treated with Stem Cell Transplantation #MM
Category: Multiple Myeloma
11 Views
Cancer-News 4 days
Improve Readiness for Stem Cell Transplant Recipients @OSUCCC_James
Improve Readiness for Stem Cell Transplant Recipients @OSUCCC_James
Category: News
17 Views
OSUCCC 5 days